Back to Journals » Clinical Epidemiology » Volume 10

Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study [Corrigendum]

Authors Ankarfeldt MZ, Thorsted BL, Groenwold RHH, Adalsteinsson E, Ali MS, Klungel OH

Received 18 October 2018

Accepted for publication 18 October 2018

Published 28 November 2018 Volume 2018:10 Pages 1787—1788

DOI https://doi.org/10.2147/CLEP.S191335


Ankarfeldt MZ, Thorsted BL, Groenwold RHH, et al. Clin Epidemiol. 2017;9:19–30.
 

On page 23, Figure 1 Notes section was marked incorrectly. The correct Notes should read as follows:
Figure 1 Propensity score over time for GLP-1 versus basal insulin initiators.
Notes: Blue: insulin, red: GLP-1.
Abbreviation: GLP-1, glucagon-like peptide-1 analogs.
 
On page 24, Figure 2 Notes section was marked incorrectly. The correct Notes should read as follows:
Figure 2 Propensity score over time for DPP-4i versus sulfonylurea initiators.
Notes: Blue: sulfonylurea, red: DPP-4i.
Abbreviation: DPP-4i, dipeptidyl peptidase-4 inhibitors.
 
On Page 3 of Supplementary materials, Figure S2 caption was shown incorrectly. The correct caption should read as follows:
Figure S2 Histograms of propensity score over time. Intention-to-treat and perprotocol cohorts of all identified initiators of GLP-1 and insulin, and DPP-4i and sulfonylurea, respectively. Blue: insulin and sulfonylurea initiators, respectively. Red: GLP-1 and DPP-4i initiators, respectively.
 
Despite the above corrections, the interpretation of these figures in the published proof and the Supplementary materials was correct.
 
Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]